

Table 1. Clinical and biological data of the patients included in the study groups:

Variable	Normal LC group (N = 150)	Difficult LC group (N = 105)	p-Value
<b>Age (mean±SD, years)</b>  (mean, range, median)	52.4 (± 16.2) Range: (19.0; 90.0) 52(IQR 12)	57.1 (± 14.2) Range: (19.0; 83.0) 57(IQR 16)	0.009 <sup>a</sup> *)
<b>Leukocytes (cells/microliter)</b>  (mean, range, median)	9622.5 (± 4170.5) Range: (2100.0; 31000.0) <b>8700.0 (IQR 4987.5)</b>	12731.6 (± 7216.8) Range: (3900.0; 51200.0) <b>11400.0 (IQR 7100.0)</b>	<0.001 <sup>a</sup> *)
<b>Neutrophils (%)</b>  (mean, range, median)	0.7 (± 0.1) Range: (0.3; 0.9) <b>0.7 (IQR 0.1)</b>	0.7 (± 0.1) Range: (0.1; 0.9) <b>0.7 (IQR 0.3)</b>	0.001 <sup>a</sup> *)
<b>Lymphocytes (%)</b>  (mean, range, median)	0.2 (± 0.1) Range: (0.01; 0.6) 0.18 (IQR 0.17)	0.1 (± 0.1) <b>Range: (0.004; 0.8)</b> <b>0.13 (IQR 0.15)</b>	0.002 <sup>a</sup> *)
<b>NLR</b>  (mean, range, median)	6.3 (± 7.8) Range: (0.4; 50.74) <b>3.98 (IQR 4.8)</b>	11.06 (± 25.05) Range: (0.02; 232.5) <b>6.2 (IQR 6.72)</b>	0.001 <sup>a</sup> *)
<b>Thrombocytes (cells/microliter)</b>  (mean, range, median)	247622.7 (± 81254.3) Range: (74000.0; 763000.0) <b>244500.0 (IQR 87000.0)</b>	264731.4 (± 174673.6) Range: (68000.0; 1700000.0) <b>240000.0 (IQR 103000.0)</b>	0.839 <sup>a</sup> )
<b>Fibrinogen (mg/dL)</b>  (mean, range, median)	409.8 (± 127.3) Range: (189.4; 990.0) <b>374.5 (IQR 129.03)</b>	574.5 (± 238.7) Range: (206.0; 1220.0) <b>570.0 (IQR 351.0)</b>	<0.001 <sup>a</sup> *)
<b>INR (UI/L)</b>  (mean, range, median)	1.2 (± 0.3) Range: (0.9; 3.7) <b>1.15 (IQR 0.16)</b>	1.3 (± 1.2) Range: (0.9; 13.2) <b>1.21 (IQR 0.22)</b>	0.021 <sup>a</sup> *)

<b>AST (UI/L)</b> (mean, range, median)	54.6 (± 86.4) Range: (2.4; 664.0) <b>28.0 (IQR 28.75)</b>	57.5 (± 99.9) Range: (7.0; 952.0) <b>30.0 (IQR 44.0)</b>	0.532 <sup>a)</sup>
<b>ALT (UI/L)</b> (mean, range, median)	74.8 (± 90.6) Range: (1.3; 532.0) <b>46.0 (IQR 44.0)</b>	70.8 (± 89.4) Range: (11.0; 627.0) <b>37.0 (IQR 53.0)</b>	0.17 <sup>a)</sup>
<b>Total Bilirubin (mg/dL)</b> (mean, range, median)	1.1 (± 1.3) Range: (0.2; 10.4) <b>0.7 (IQR 0.6)</b>	1.2 (± 1.9) Range: (0.2; 11.1) <b>0.7 (IQR 0.6)</b>	0.715 <sup>a)</sup>
<b>Creatinine (mg/dL)</b> (mean, range, median)	0.8 (± 0.3) Range: (0.3; 3.5) <b>0.8 (IQR 0.2)</b>	0.9 (± 0.5) Range: (0.4; 3.1) <b>0.82 (IQR 0.3)</b>	0.187 <sup>a)</sup>
<b>Tongyoo score</b>	2.9±1.4 Range: (0; 6.0) 2.5(IQR 2.0)	6.0(± 2.6) Range: (2.0; 13.0) 6.0(IQR 2.1)	<0.001 <sup>a)</sup> *

Footnote: <sup>a)</sup> p- value was assessed with the Mann-Whitney. The alpha risk was set to 5% ( $\alpha = 0.05$ ); <sup>b)</sup> p- value was tested with the Chi-squared test. The alpha risk was set to 0.05; \*statistically significant; ASA - The American Society of Anesthesiologists (ASA) physical status classification system; NLR: neutrophil-to-lymphocyte ratio; CBD: common bile duct.

**Table 2.** Imagistic data of the patients included in the study

Variable	Normal LC (N = 150)	Difficult LC (N = 105)	p-Value
CBD (mm) (mean, range, median)	5.0 (± 2.3) Range: (3.0; 18.0) 4.0 (IQR 1.0)	5.0 (± 2.0) Range: (3.0; 13.0) 4.0 (IQR 1.0)	0.546 <sup>a)</sup>
Transverse diameter of GB (mm) (mean, range, median)	28.8 (± 7.9) Range: (3.0; 58.0) 29.5 (IQR 7.0)	36.5 (± 12.3) Range: (15.0; 77.0) 35.0 (IQR 12.0)	<0.001 <sup>a)</sup> *
Length of GB (mm) (mean, range, median)	79.5 (± 18.6) Range: (25.3; 140.5)	93.3 (± 27.2) Range: (40.1; 175.4)	<0.001 <sup>a)</sup> *

	79.7 (IQR 24.7)	90.3 (IQR 40.0)	
Thickness of GB wall (mm) (mean, range, median)	4.2 ( $\pm$ 1.5) Range: (2.0; 10.0) 4.0 (IQR 2.0)	6.1 ( $\pm$ 2.9) Range: (2.0; 22.0) 6.0 (IQR 3.0)	<0.001 <sup>a)</sup> *

Footnote: <sup>a)</sup> p- value was assessed with the Mann-Whitney. The alpha risk was set to 5% ( $\alpha$  = 0.05); <sup>b)</sup> p-value was tested with the Chi-squared test. The alpha risk was set to 0.05; \*statistically significant;